Journals / Erciyes Tıp Dergisi / 2005 / Cilt: 27 - Sayı: 4

Cardiovascular effects of leptin

Leptinin kardiyovasküler etkileri

Pages
167–176
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present article the renal, vascular, cardiac actions and sympathoactivation of hyperleptinemia and their relevance to cardiovascular diseases were reviewed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Obesity is a risk factor for cardiovascular diseases, in particular for hypertension.
📊
Key Findings & Data:Leptin levels are increased in obesity and leptin exhibits cardiovascular actions that may contribute to increased cardiovascular risk.
💡
Conclusion & Impact:In the present article the renal, vascular, cardiac actions and sympathoactivation of hyperleptinemia and their relevance to cardiovascular diseases were reviewed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Obesity is a risk factor for cardiovascular diseases, in particular for hypertension. Leptin levels are increased in obesity and leptin exhibits cardiovascular actions that may contribute to increased cardiovascular risk. Excess weight gain is a major risk factor for essential hypertension and end-stage renal disease. Obesity raises blood pressure by increasing renal tubular sodium reabsorption, impairing pressure natriuresis, causing volume expansion because of activation of the sympathetic nervous system and renin-angiotensin system and by physical compression of the kidneys, especially when visceral obesity is present. In the long-term, however, these changes, along with the increased systemic arterial pressure, create a hemodynamic burden on the kidneys that causes glomerular injury. Leptin, a product of the obesity gene, plays an important role in the regulation of body fat. Leptin resistance possesses cardiorenal actions potentially contributing to obesity related hypertension including generalized sympathoactivation. Interactions between angiotensin II, insulin and endothelin-A with hyperleptinemia could have deleterious cardiovascular effects in obesity. In the present article the renal, vascular, cardiac actions and sympathoactivation of hyperleptinemia and their relevance to cardiovascular diseases were reviewed.

Özet

Obezite kardiyovasküler hastalık için bir risk faktörü olup leptin seviyesinde artışla birliktedir. Leptinin kardiyovasküler etkileri bulunmaktadır. Bu derlemede, obezitede artmış leptin direncine bağlı gelişen hiperleptineminin renal, kalp, damar sistemleri ve sempatik sinir sistemi aktivitesi üzerine etkileri ve bunların kardiyovasküler hastalık ile ilişkisi gözden geçirilecektir. Aşırı kilo, esansiyel hipertansiyon ve son dönem renal hastalık için en önemli risk faktörüdür. Özellikle viseral obezitede, sempatik sinir sistem ve buna bağlı renin-anjiyotensin sistem aktivitesinin artması, böbrekler üzerine oluşan fiziksel kompresyon renal tübüler sodyum geri emiliminin artmasına neden olur. Ekstrasellüler sıvı volüm artar. Uzun sürede bu değişiklikler, böbreklerde hemodinamik bozukluklara ve en sonunda da glomerüler hasara neden olmaktadır. Obezite gen ürünü leptin, vücut yağ regülasyonunda rol oynar. Obezite ilişkili hipertansiyon nedenlerinden olan sempatik aktivasyon artışında hiperleptineminin etkisi vardır. Anjiyotensin II, insulin ve endotelin-A ile hiperleptinemi arasındaki etkileşim, obezitede görülen kardiyovasküler bozukluğun nedenlerindendir.

🔖

Cite This Article

DURSUN, N. (2022). Cardiovascular effects of leptin. Erciyes Tıp Dergisi, Cilt: 27 - Sayı: 4, 167–176. https://ajindex.com/articles/502811

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. J.Ren. Leptin and hyperleptinemia- from friend to foe for cardiovascular function. J Endocrin 2004; 181: 1-10
  2. Bartun M, Carmona R, Ortmann J, Kneger JE et al. Obesity- associated activation of angiotensin and endothelin in the cardiovascular system. IJ BCB, 2003; 3:826-837
  3. Hall J E, Henegar JR, Dwyer TM, Liu J et al. Is obesity a major cause of chronic kidney disease. Adv Renal Replace Th, 2004; 11(1): 41-54
  4. Hall JE, Crook ED, Jones DW, Wofford MR and Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci, 2002; 324: 127-137
  5. Zhang W, Telemague-Potts S, Andersan PR, Wang Z. et al. Adenoviral leptin as gene therapy for obesity related hypertension. Am J Hypertens 2002;15: 1A (Abstract)
  6. Friedmen JM. The function of leptin in nutrition, weight and physiology, Nutr Rev 2002; 60:51-514
  7. Ahima RS, Osei SY. Leptin signaling. Phys Behav 2004; 81 223-241
  8. Tartaglia LA. The leptin receptor. J Biol Chem 1997;272: 6093-6096
  9. Peelman F, Waelput W, Iserentat H et al. Leptin: linking adipocite metabolism with cardiovascular and autoimmune disease. Prog Lipid Res 2003; 43: 283-301
  10. Chua SC, Chung WK Wu-Peng Xset al. Phetypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996;271: 1994-1996 11. Clement K, Vaisse C, Nahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401
  11. Wu-Peng XS, Chua SC, Okada N, Liu SM, Nicolson M, Leibel RL. Phenotype of the obes Koletsky(f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor( Lepr): evidence for deficient plasma-to-CSI transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 1997;46: 513-518
  12. Banks WA. The many lives of leptin. Peptides 2004;25: 331-338
  13. Bjorback C,, Elmquist JK, Michl P et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 1998; 139: 3485-3491
  14. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997;99: 14-18
  15. Takaya K, Ogawa Y, Hiraoka J et al. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 1996; 14: 130-131. 17.Muraoka O, Xu B, Tsurumaki T et al. Leptin-induced transactivation of NPY gene promoter mediated by JAK 1, JAK2 and STAT 3 in the neural cell lines. Neurochem Int 200